Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies
PublisherBMJ Publishing Group
MetadataShow full item record
AbstractObjectives: To investigate the practice of post-marketing studies in Germany during a three year period and to evaluate whether these trials meet the aims specified in the German Medicinal Products Act. Design: Survey of notifications submitted to German regulatory agencies before post-marketing studies were carried out, 2008-10. Setting: Notifications obtained through freedom of information requests to the three authorities responsible for registering post-marketing studies in Germany. Main outcome measures: Descriptive statistics of post-marketing studies, including the products under study, intended number of patients, intended number of participating physicians, proposed remunerations, study plan and protocol, and availability of associated scientific publications and reports on adverse drug reactions. Results: Information was obtained from 558 studies, with a median of 600 (mean 2331, range 2-75 000) patients and 63 (270, 0-7000) participating physicians per study. The median remuneration to physicians per patient was €200 (€441, €0-€7280) (£170, £0-£6200; $215, $0-$7820), with a total remuneration cost of more than €217m for 558 studies registered over the three year period. The median remuneration per participating physician per study was €2000 (mean €19 424), ranging from €0 to €2 080 000. There was a broad range of drugs and non-drug products, of which only a third represented recently approved drugs. In many notifications, data, information, and results were, by contract, strictly confidential and the sole property of the respective sponsor. No single adverse drug reaction report could be identified from any of the 558 post-marketing studies. Less than 1% of studies could be verified as published in scientific journals. Conclusions: Post-marketing studies are not improving drug safety surveillance. Sample sizes are generally too small to allow the detection of rare adverse drug reactions, and many participating physicians are strictly obliged to maintain confidentiality towards the sponsor. High remuneration and strict confidentiality clauses in these studies could influence the physicians’ reporting behaviours of adverse drug reactions.
CitationSpelsberg, A., Prugger, C., Doshi, P., Otrowski, K., Witte, T., Hüsgen, D. & Keil, U. (2017). Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. DOI: doi.org/10.1136/bmj.j337
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/6620
- Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
- Authors: Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X
- Issue date: 2017 Dec
- [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005].
- Authors: Weisser K, Meyer C, Petzold D, Mentzer D, Keller-Stanislawski B
- Issue date: 2007 Nov
- Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
- Authors: Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC
- Issue date: 2011 May
- A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
- Authors: Hoffman KB, Dimbil M, Kyle RF, Tatonetti NP, Erdman CB, Demakas A, Chen D, Overstreet BM
- Issue date: 2015 Dec
- The marketplace can't give us the drug safety data we need.
- Authors: Avorn J
- Issue date: 2007 Feb 9